Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One-Centre experience with TDM

Abstract

The aim of this article is to demonstrate extreme interindividual variability of piperacilin/tazobactam (PIP/TAZO) pharmacokinetics in critically ill morbidly obese patients and to emphasize the need for the practice of routine PIP/TAZO plasma concentrations measurement in order to ensure optimal efficacy and safety of antibiotic therapy.

Keywords

• critical illness
• morbid obesity
• piperacillin/tazobactam (PIP/TAZO)
• therapeutic drug monitoring (TDM)